|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Cancer Overview - Lung, Brain, Head and Neck, Thyroid
Datamonitor, July 2008, Pages: 328
In 2008, the six tumor types covered in this report are forecast to account for over 666,000 new cases of cancer, obviously representing an enormous market potential. However, it is the higher-incidence tumor types that continue to attract drug developers, with lower-incidence cancers potentially suffering due to unfulfilled unmet needs via a lack of R&D activity.
Scope
- Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types
- Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
- Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types
- Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs
Highlights of this title
A low level of interest from drug developers means unmet needs in the SCLC, mesothelioma, primary brain and thyroid cancer markets are likely to remain unfulfilled. Drug developers should realize that despite being low-incidence tumor types, high unmet needs could result in significant financial rewards and a foothold in the market to build upon.
Erbitux (cetuximab; ImClone/Bristol-Myers Squibb/Merck Serono) shows the most promise in the current NSCLC pipeline. Recent clinical trial results mean Erbitux may become a viable option in the first-line treatment of NSCLC, particularly for those patients ineligible for Avastin (bevacizumab; Genentech/Roche) therapy.
Vectibix (panitumumab; Amgen) and zalutumumab (HuMax-EGFR; Genmab/Medarex) show great promise to compete with Erbitux in the head and neck cancer market, particularly due to potential toxicity advantages that fully human monoclonal antibodies may have.
Key reasons to purchase this title
- Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment
- Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction
- Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products
Customers who bought this item also bought
Women’s and Breast Imaging
Neuroradiology Review
Head To Toe Imaging
Anatomy and Physiology for the Manual Therapies, 1st Edition
Global Cancer Focus Company Directory
Pipeline Insight: Cancer Overview - Increasing Diversity Offers Both High Risk and Reward
Biomarkers - Technologies, Markets and Companies
Positron Emission Tomography (PET) Markets
Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Molecular Diagnostics - Technologies, Markets and Companies
|
|
|
|
